A Mutation Outside the Dimerization Domain Causing Atypical STING-Associated Vasculopathy With Onset in Infancy

Rohit G. Saldanha1,2†, Katherine R. Balka3,4†, Sophia Davidson3,4, Brynn K. Wainstein1,2, Melanie Wong5, Rebecca Macintosh6, Christine K. C. Loo7, Martin A. Weber7,8, Vasanth Kamath7, CIRCA9, AADRY10, Fiona Moghaddas3,4, Dominic De Nardo3,4, Paul Edgar Gray1,2* and Seth Lucian Masters3,4*

1 Department of Immunology and Allergy, Sydney Children’s Hospital Randwick, Sydney, NSW, Australia, 2 School of Women and Children’s Health, University of New South Wales, Sydney, NSW, Australia, 3 Inflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia, 4 Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia, 5 Children’s Hospital at Westmead, Westmead, NSW, Australia, 6 Department of Medical Genetics, Sydney Children’s Hospital, Randwick, NSW, Australia, 7 Department of Anatomical Pathology, NSW Health Pathology, Prince of Wales Hospital, Sydney, NSW, Australia, 8 School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia, 9 Clinical Immunogenomics Consortium Australia, Sydney, NSW, Australia, 10 Australian Autoinflammatory Diseases Registry, Melbourne, VIC, Australia

Background: Mutations in the gene encoding stimulator of interferon genes (STING) underlie a type I interferon (IFN) associated disease, STING-associated vasculopathy with onset in infancy (SAVI). Patients suffer cutaneous vasculopathy and interstitial lung disease, but are not known to suffer life-threatening infection.

Case: We describe a child who presented with Pneumocystis jirovecii pneumonia in early life, from which he recovered. He went on to suffer failure to thrive, developmental delay, livedo reticularis, and vesicular rash, but without cutaneous vasculitis, and with normal C-reactive protein and erythrocyte sedimentation rates. At 3 years of age, he developed life-threatening pulmonary hypertension.

Methods: Whole genome sequencing (WGS) was performed using the Illumina HiSeqX10 platform and the Seave platform was used for bioinformatic analysis. mRNA expression of IFN-stimulated genes and inflammatory cytokines from peripheral blood mononuclear cells was determined by quantitative polymerase chain reaction. Luciferase assay was used to model IFNβ and NF-κB activity in vitro.

Results: WGS revealed a de novo mutation p.Arg284Ser in STING at an amino acid previously associated with SAVI. Although this mutation did not fall in the dimerization domain (DD), mRNA analysis revealed constitutive IFN-gene activation consistent with an interferonopathy, which correlated to STING activation in vitro. The patient was treated with corticosteroids and the JAK inhibitor Ruxolitinib, resulting in a rapid improvement of pulmonary hypertension, general well-being, and resolution of the IFN gene signature. However, he did go on to evolve a nasal septal erosion suggesting incomplete control of disease.
INTRODUCTION

Type I interferons (IFNs α and β) play a crucial role in immune mediated protection from viral infection. Stimulator of interferon genes (STING), encoded by the gene *TMEM173*, is a key intermediate in activating this type I IFN response (1). Once activated, STING induces the phosphorylation of transcription factors IRF3 and NF-κB, promoting their nuclear translocation and the transcription of IFNs and inflammatory cytokines, respectively. Type I IFNs act via the IFN α/β receptor (IFNAR), which in turn activates a number of downstream signaling pathways, most notably the JAK–STAT pathway. IFNAR agonism leads to the transcriptional regulation of over 2,000 genes, referred to as IFN-stimulated genes (ISGs). Heterozygous gain-of-function (GoF) mutations in *TMEM173* result in constitutive activation of STING and the clinical syndrome known as STING-associated vasculopathy with onset in infancy (SAVI) (2). To date, a total of seven GoF mutations have been reported to induce SAVI, a disease characterized by neonatal–onset inflammation with raised inflammatory markers, cutaneous vasculopathy, and interstitial lung disease (2–9). SAVI has been classified as an interferonopathy as it is characterized by elevated levels of type I IFNs and ISGs. Activation of STING also triggers NF-κB, and mouse models suggest that this could contribute to the pathogenesis of SAVI (10). Typically, activation of NF-κB is associated with increased C reactive protein (CRP) in patients with inflammation, and CRP is also elevated in SAVI.

CASE

A 3-year-old boy born to non-consanguineous parents of Chinese/Malaysian ethnicity presented at 2 months of age with acute respiratory distress requiring mechanical ventilation and an opportunistic infection are notable, and raise the possibility that variants outside the STING DD may potentially manifest with an atypical SAVI phenotype. Nevertheless, there was an objective clinical improvement in response to JAK inhibition.

Keywords: stimulator of interferon genes, STING-associated vasculopathy with onset in infancy, interferon, NF-κB, JAK, immunodeficiency

Conclusion: This case provides molecular evidence to support the p.Arg284Ser variant in STING exerting pathogenicity through a gain-of-function mechanism. The lack of cutaneous vasculitis or elevated systemic inflammatory markers, and the occurrence of an opportunistic infection are notable, and raise the possibility that variants outside the STING DD may potentially manifest with an atypical SAVI phenotype. Nevertheless, there was an objective clinical improvement in response to JAK inhibition.
FIGURE 1 | Continued
the protein STING (Figure 2A). The variant was confirmed by Sanger sequencing, and is not present in the Exac database (11). In silico analysis predicted the mutation to be pathogenic based on; the physiochemical difference between arginine and serine (Grantham score 110); SIFT prediction (deleterious), PolyPhen (probably damaging), CADD (scaled = 26.7), mutation taster (disease causing), and Provean (deleterious). Interestingly, a previous case report documented a different de novo change in the same amino acid residue; c850A>G (pArg284Gly, R284G) in a patient suffering from SAVI with upregulation of IFN genes secondary to constitutive STING activation (8).

We hypothesized the substitution of a serine for an arginine at position 284 in TMEM173 would result in constitutive activation of STING and consequently, autoinflammatory disease characterized by IFNαβ and NF-κB activation. To investigate this, peripheral blood mononuclear cells (PBMCs) were isolated from patient blood samples and analyzed for mRNA expression of ISGs and inflammatory cytokines by quantitative polymerase chain reaction (qPCR). Compared to healthy controls (HCs) our patient showed an IFN-gene signature with markedly raised levels of IFNB1 and the ISGs IFNA1, ISG15, IRF7, and MX1 supporting the diagnosis of an interferonopathy (Figures 2B–F). We also interrogated the mRNA expression of several NF-κB-dependent inflammatory cytokines; TNF, IL6, and IL1B. Interestingly, while TNF was not elevated, IL6 and IL1B were significantly upregulated (Figures 2G–I).

We next sought to directly determine if R284S triggers STING activation. STING expression plasmids encoding R284S and other known SAVI mutations (Figure 2A) were created by site-directed mutagenesis for in vitro studies. We then transfected HEK293T cells with wild-type (WT) and mutant versions of STING before assessing IFNβ and NF-κB activation using luciferase reporter systems. The R284S mutant STING induced high IFNβ activity compared to WT STING, similar to the previously published STING GoF mutants (Figure 2J). We further found that all SAVI mutants assayed, including R284S, induced markedly enhanced NF-κB activation compared to WT STING (Figure 2K). Therefore, in vitro analysis confirms R284S as a pathogenic GoF STING mutation.

After confirming the diagnosis of an interferonopathy, the patient was treated with a combination of oral prednisolone (2 mg/kg/day) and the JAK 1/2 inhibitor Ruxolitinib (5 mg daily) (12) which was well tolerated. His mobility and demeanor improved within days of steroid therapy including quality of sleep, respiratory effort, and cessation of his frequent vomiting episodes. His appetite improved, with weight gain of approximately 1.5 kg in 4 weeks. Serial weight velocity has subsequently increased from <3rd to 20th percentile in 5 months. His pulmonary pressures became sub-systemic within 8 weeks of sildenafl, steroids, and Ruxolitinib therapy. Initial steroid therapy coincided with a notable neurodevelopmental improvement. He made rapid gains in mobility (gross motor), self-feeding (fine motor), sleep/social interactions (personal social), and receptive speech (communication) compared to previous years while remaining unable to speak.

Immune phenotyping was performed at 2 months of age when the patient presented with Pneumocystis jirovecii pneumonia and more recently at 37 months of age during a routine follow-up. Lymphocyte proliferation performed at 9 months shows an index ratio of mean counts per minute with antigen stimulation per mean count per minute without antigen stimulation. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; NR, normal range; PHA, phytohemagglutinin.
FIGURE 2 | R284S is a pathogenic gain-of-function stimulator of interferon genes (STING) mutation. (A) Schematic structure of human STING: four transmembrane domains (TM, green), the dimerization domain (DD, purple), the C-terminal tail (CTT, red) region, and indicating the locations of known STING-associated vasculopathy with onset in infancy (SAVI) mutations. (B–I) Peripheral blood mononuclear cells (PBMCs) were isolated from the patient and three healthy controls (HC) and analyzed ex vivo for expression of inflammatory mediators by quantitative polymerase chain reaction (qPCR) analysis. Data for HC are shown as mean ± SEM of the three individuals. (J) IFNβ and (K) NF-κB luciferase reporter activity was monitored following transfection of HEK293T cells with an empty vector (EV) control, wild-type (WT) STING, or the indicated SAVI mutants of STING. Firefly luciferase reporter activity was normalized to the renilla control and presented as relative luciferase units (RLU). Data are representative of four independent experiments and shown as mean ± SD of three technical replicates. (L) Heatmap showing the mRNA expression of indicated inflammatory mediators as measured by qPCR analysis of PBMCs from the patient R284S before (−) or after (+) treatment with JAK inhibitor Ruxolitinib. This is compared to three HCs, with data shown relative to HC1.

DISCUSSION

The clinical phenotype in almost all SAVI patients has included persistent systemic inflammation, cutaneous rash, failure to thrive, vasculitis of varying degrees, and interstitial lung disease (2–9). There are now two reports of pulmonary arterial hypertension in SAVI, presumed secondary to interstitial lung disease (4, 9). This may be the case in our patient, where a full work-up of the chest was not possible. However, our patient displays atypical features for SAVI, with no evidence of vasculitis or ongoing systemic inflammation, an atypical skin rash, and presentation with opportunistic...
infection, which suggested primary immunodeficiency. A different mutation at the same site as our patient, reported by Melki et al. (R284G) had interstitial lung disease but no significant inflammation, leading to suggestions of phenotypic differences between the two main sites of GoF mutations in STING (8).

Even more salient to the current case, while this manuscript was in preparation, Konno et al. described a 9-month-old infant with the same de novo heterozygous mutation in STING (p.R284S) (13). That patient presented without typical features of SAVI, but with a severe neck abscess, and later succumbed to pneumonia. In vitro studies conducted by Konno et al. agree with the data presented here that the p.R284S STING mutation is constitutively active. Significantly, we were able to confirm this finding through ex vivo analysis of patient cells. R284 is located within the cyclic dinucleotide binding domain of STING; however, its mutation does not seem to alter ligand affinity (8, 13). An alternate explanation could be that R284S changes/blocks the ubiquitination of STING at K289, which may increase its activation when stimulated (14), or that this region is required for appropriate shuttling of STING between the endoplasmic reticulum and Golgi (15). Overall, our study and that of Konno et al. provide more evidence that mutations outside the dimerization interface still cause GoF SAVI, but may present with atypical disease symptoms. A summary and comparison of the findings from all three patients with heterozygous GoF mutations in STING R284 is presented in Table 2.

Infections have not been a predominant part of SAVI, although patients may have recurrent bacterial upper respiratory infections (including pseudomonas infections), which is likely to be attributable to structural predisposition to infection from evolving interstitial lung disease rather than an immune defect (2–9). Patients have also demonstrated lymphopenia, a feature seen in the first STING GoF (N153S) mutant mouse (10). Recently, Bouis et al. characterized another heterozygous STING mutation in mice (V154M) which demonstrated a severe combined immunodeficiency phenotype affecting T/B/NK cell numbers (16). This was associated with an intrinsic defect in anti-CD3/CD28 T cell proliferation that was partially IFN dependent and correlates with our phenotypic observation of reduced anti-CD3/CD8 stimulated cell proliferation and immunodeficiency in our patient. From this perspective, it is noteworthy that our patient demonstrated a poor response to anti-CD3 but not to PHA stimulation in early life. An intriguing feature of our patient is that he never relapsed with Pneumocystis jiroveci pneumonia (PJP) after coming off co-trimoxazole, which would be unusual for a patient with a primary immunodeficiency predisposing to this organism, such as CD40L deficiency. Therefore, perhaps this predisposition reduced over time. In terms of a link between STING and PJP predisposition, type I IFNs are thought to play a role in the control of this fungus (17); however, linking constitutive STING activation to Pneumocystis infection remains speculative.

The STING N153S mutant mouse closely resembles some manifestations of SAVI such as splenomegaly, pleural effusions, respiratory distress, and ulcerative skin lesions (10). Interestingly, when crossed to mice deficient in IRF3 (preventing the production of IFNβ via STING) the mice still developed dysregulation of immune cells and lung disease. Therefore, NF-κB-dependent cytokines may play a dominant role in the phenotype observed for this SAVI mouse model. However, while the N153S mice developed chronic perivascular inflammation and organized

### Table 2 | Comparison of phenotypic changes associated with heterozygous mutation at p.R284 stimulator of interferon genes reported in the literature and this study.

| Phenotype | R284G (8) | R284S (13) | R284S |
|-----------|----------|------------|-------|
| Sex       | F        | M          | M     |
| Age       | 25 years (alive) | 9 months (deceased) | 3 years (alive) |
| Cutaneous lesions | Livido | NIL | Livido |
|           | Acrocyanosis | NIL | Acral neutrophilic dermatosis |
|           | Palatal/nasal septum necrosis | NIL | Nasal septum necrosis |
| Lungs     | Interstitial lung disease (ILD) | ND | Pulmonary hypertension |
| Infection | Recurrent bacterial infections in early life | Neck abscess | Fatal pneumonia |
|           |         |         | PJP infection at 2 months of life |
| Elevated CRP/ESR | NIL | NIL | NIL |
| Immune perturbations | ND | ND | Reduced CD3/CD8 lymphocyte proliferation |
| Transcription factor activation and binding | | | |
| IRF3 phosphorylation | +++ (HEK293T cells) | +++ (MEF cells) | ND |
| INFγ reporter activity | ++ (HEK293T cells) | +++ (HEK293T cells) | ++ (HEK293T cells) |
| NF-κB reporter activity | ND | +++ (HEK293T cells) | ++ (HEK293T cells) |
| STAT1 phosphorylation | +++ (ex vivo PBMCs) | +++ (MEF cells) | ND |
| Cytokine expression | | | |
| Type 1 IFN | ND | − (MEF cells) | +++ (ex vivo PBMCs) |
| IL1 | ND | ND | +++ (ex vivo PBMCs) |
| IL6 | ND | ++ (serum) | +++ (ex vivo PBMCs) |
| TNF | ND | ND | − (ex vivo PBMCs) |
| Response to treatment with JAK inhibitor | | | |
| In vitro assay | +ve (ruxolitinib) | +ve (tofacitinib) | ND |
| Ex vivo assay | ND | ND | +ve (ruxolitinib) |
| In vivo treatment | NIL | Deceased | Yes (ruxolitinib) |

ILD, interstitial lung disease; MEF, mouse embryonic fibroblasts; ND, not done; PBMCs, peripheral blood mononuclear cells; PJP, Pneumocystis jiroveci pneumonia; ESR, erythrocyte sedimentation rate; CRP, C reactive protein.

*In vitro reconstitution of TMEM173-/- MEF cells.
thrombosis in pulmonary blood vessels, they did not develop the pulmonary fibrosis observed in SAVI and demonstrated a milder upregulation of the type I IFN signature compared to their human counterparts. This provides an interesting comparison to the atypical features observed in our patient with the R284S mutation. While the acute pulmonary hypertensive crisis was attributed to interstitial lung disease common to SAVI cases, the patient did not demonstrate clinical signs of lung parenchymal disease (tachypnea or hypoxemia). Moreover, his overnight pulse oximetry studies revealed a normal oxygen saturation range >92% in ambient room air. We surmise that the pulmonary hypertension in the absence of clinically evident lung disease might represent a primary vascular pathological process similar to that seen in the SAVI mouse model. Whether mutations in R284 can result in preferential, site-specific vasculitis given the absence of cutaneous vasculitis in our patient is unknown. It would be very interesting to know if a mouse model encoding a mutation analogous to R284S could reveal a different phenotype and help to explain why mutations outside the dimerization domain of human STING display features atypical of SAVI.

This case reinforces the atypical presentation of two previous patients with mutations at position R284 and raises the possibility that variants at this locus may present a different phenotype to patients with variants elsewhere in the STING protein. This is the first patient with a STING GoF mutation documented to suffer from PJP infection, which is an important consideration for SAVI patients who display lymphopenia and impaired T-cell proliferation. In vitro functional analysis of the R284S STING mutation found evidence of IFN and NF-κB activation, however, did not reveal a basis for potential genotype-phenotype correlation. Our study supports the benefit of JAK inhibition with Ruxolitinib for patients who display lymphopenia and impaired T-cell proliferation from PJP infection, which is an important consideration for SAVI patients with variants elsewhere in the STING protein. This provides an interesting comparison to the atypical features observed in our patient with the R284S mutation analogous to R284S could reveal a different phenotype and help to explain why mutations outside the dimerization domain of human STING display features atypical of SAVI.

METHODS

Patient and Study Approval

Written informed consent for publication of this case report was obtained from the patients guardians. The patient was consented for WGS under South East Sydney Local Health District ethics (HREC/11/POWH/152). The patient was recruited to the Australia Autoinflammatory Diseases Registry (AADRY, HREC/15/Mon/31) for ex vivo examination of PBMCs. HC PBMC were obtained from blood collected at the Volunteer Blood Donor Registry under Walter and Eliza Hall Institute of Medical Research HREC 10/02.

Whole Genome Sequencing

Whole genome sequencing was performed using the Illumina HiSeqX10 platform, and the Seave platform was used for bioinformatic analysis.

Lymphocyte Functional Assays

Anti-CD3, anti-CD28-, and PHA-stimulated lymphocyte proliferation assays were performed on whole blood, using uptake of tritiated thymidine, as a clinical test through SA Pathology, Adelaide, South Australia.

PBMC Isolation and mRNA Expression Analysis

Human PBMCs were purified from whole blood over a Ficoll density gradient (GE Healthcare) and lysed for RNA purification using RNeasy Plus Mini Kit (Qiagen) as directed by the manufacturer. RNA was reverse transcribed to cDNA using SuperScript III Reverse transcriptase (Thermo Fisher). qPCR was performed with Maxima SYBR Green master mix (Thermo Fisher) using primers designed for the specified genes. Expression of target genes was normalized to the expression of the housekeeping gene HPRT. Primer sequences used can be provided upon request.

Generation of STING Variants

To generate plasmids expressing STING carrying the SAVI mutations a human STING cDNA template (pEF-BOS-mCitrine-hSTING) was mutated using the QuickChange Lightning Mutagenesis Kit (Agilent Technologies). The following mutagenesis primers were used:

V147L, 5′-GCTGAGATCTCTGCATTGTTGAAAAAGGG-3′; N154S, 5′-GGGAAAAAAAGGATTTTCCAGGTGGCCCATGGG-3′; R281Q, 5′-GCTGGGTTTAGCAGGAGGATTGCTGTTGAGCAGGC-3′; R284G; 5′-GGCTTTAGCCGGGAGGATGGGCCTGAGCAGGCC-3′; R284S, 5′-GGCTTTAGCCGGGAGGATGGGCCTGAGCAGGCC-3′.

Luciferase Assay

Approximately 1.5 × 10⁶ HEK293T cells were seeded per well in a 24-well tissue culture plate. In each well 500 ng of expression plasmids were transiently transfected per well along with 100 ng of either an IFNβ or NF-κB firefly luciferase reporter plasmid and 10 ng renilla plasmid as an internal control. After 24 h, cells were lysed with Passive Lysis Buffer (Promega), and luminescence was measured on a luminometer using the Dual-Luciferase Reporter Assay System substrates (Promega). Conditions were performed in technical triplicates and firefly luciferase values were normalized to the renilla control.

ETHICS STATEMENT

The patient was consented for whole genome sequencing (WGS) under South East Sydney Local Health District ethics (HREC/11/POWH/152). The patient was recruited to the Australia Autoinflammatory Diseases Registry (AADRY, HREC/15/Mon/31) for ex vivo examination of PBMCs. Healthy control PBMC were obtained from blood collected at the Volunteer Blood Donor Registry under Walter and Eliza Hall Institute of Medical Research HREC 10/02.

AUTHOR CONTRIBUTIONS

RS, BW, MW, RM, CL, MAW, VK, and PG were involved in collecting phenotypic data from the patient. KB, SD, FM, DD,
the skin biopsy; The Volunteer Blood Donor Registry; Prof. S. Kossard, Kossard Dermatopathologists, who kindly reviewed the skin biopsy; and SM performed or analyzed ex vivo and in vitro experiments. CIRCA managed genomic sequencing. AADRY managed ex vivo analysis. RS, KB, SD, FM, DD, PG, and SM wrote the manuscript.

ACKNOWLEDGMENTS

The authors would like to acknowledge: Jenni Harris for coordinating the Australian Autoinflammatory Diseases Registry and for the provision of healthy control samples through the Volunteer Blood Donor Registry; Prof. S. Kossard, Kossard Dermatopathologists, who kindly reviewed the skin biopsy; The Clinical Trials & Biorepository Team, St. Vincent’s Centre for Applied Medical Research for storage and handling of PBMC cells for ex vivo analysis.

FUNDING

SM acknowledges funding from NHMRC grants (1144282, 1142354, and 1099262), The Sylvia and Charles Viertel Foundation, HHMI-Wellcome International Research Scholarship, and Glaxosmithkline. SD acknowledges funding from NHMRC ECF: GNT1143412. Costco Wholesale Australia and the Fundraising department of The Children’s Hospital at Westmead provided generous support to enable genomic sequencing through a SCHN rare disease genomics initiative.

REFERENCES

1. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adapter that facilitates innate immune signalling. Nature (2008) 455:674–8. doi:10.1038/nature07317
2. Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Sanchez GAM, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med (2014) 371:507–18. doi:10.1056/NEJMoa1312625
3. Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest (2014) 124:5516–20. doi:10.1172/JCI79100
4. Omoymini E, Melo Gomes S, Nanthapisal S, Woo P, Standing A, Eleftheriou D, et al. Stimulator of interferon genes-associated vasculitis of infancy. Arthritis Rheumatol (2015) 67:808. doi:10.1002/art.38998
5. Chia J, Eroglu FK, Ozan S, Orhan D, Montaletre-Sanchez G, De Jesus AA, et al. Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy. J Am Acad Dermatol (2016) 74:186–9. doi:10.1016/j.jaad.2015.10.007
6. Picard C, Thouvenin G, Kannengiesser C, Dubus JC, Jeremiah N, Ruex-Laucht F, et al. Severe pulmonary fibrosis as the first manifestation of interferonopathy (TMEM173 mutation). Chest (2016) 150:e65–71. doi:10.1016/j.chest.2016.02.682
7. Konig N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tungler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis (2017) 76:468–72. doi:10.1136/annrheumdis-2016-209841
8. Melki I, Rose Y, Uggettini C, Van Eyck L, Fremond ML, Katabayashi N, et al. Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling. J Allergy Clin Immunol (2017) 140:543–552e545. doi:10.1016/j.jaci.2016.10.031
9. Yu ZX, Zhong LQ, Song HM, Wang CY, Wang W, Li J, et al. [Stimulator of interferon genes-associated vasculopathy with onset in infancy: first case report in China]. Zhonghua Er Ke Za Zhi (2018) 56:179–85. doi:10.3760/cma.j.issn.0578-1310.2018.03.005
10. Warner JD, Izirarry-Caro RA, Bennion BG, Ai TL, Smith AM, Miner CA, et al. STING-associated vasculopathy develops independently of IRF3 in mice. J Exp Med (2017) 214:3279–92. doi:10.1084/jem.20171351
11. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature (2016) 536:285–91. doi:10.1038/nature19057
12. Fremond ML, Rodero MP, Jeremiah N, Belot A, Jeziorski E, Duffy D, et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol (2016) 138:1752–5. doi:10.1016/j.jaci.2016.07.015
13. Konno H, Chinn IK, Hong D, Orange JS, Lupski JR, Mendoza A, et al. Pro-inflammation associated with a gain-of-function mutation (R284S) in the innate immune sensor STING. Cell Rep (2018) 23:1112–23. doi:10.1016/j.celrep.2018.03.115
14. Ni G, Konno H, Barber GN. Ubiquitination of STING at lysine 224 controls IRF3 activation. Sci Immunol (2017) 2(11):eaah7119. doi:10.1126/sciimmunol.aah7119
15. Dobbs N, Burnaevskiy N, Chen D, Gonugunta VK, Alto NM, Yan N. STING activation by translocation from the ER is associated with infection and autoinflammatory disease. Cell Host Microbe (2015) 18:157–68. doi:10.1016/j.chom.2015.07.001
16. Bouis D, Kirstetter P, Arbogast F, Lamon D, Delgado V, Jung S, et al. Severe combined immunodeficiency in sting V154M/WT mice. J Allergy Clin Immunol (2016). doi:10.1016/j.jaci.2018.04.034
17. Prigge JR, Hoyt TR, Dobrinen E, Capecchi MR, Schmidt EE, Meissner N. Type I IFNs act upon hematopoietic progenitors to protect and maintain hematopoiesis during pneumocystis lung infection in mice. J Immunol (2015) 195:5347–57. doi:10.4049/jimmunol.1501553

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Author/s:
Saldanha, RG; Balka, KR; Davidson, S; Wainstein, BK; Wong, M; Macintosh, R; Loo, CKC; Weber, MA; Kamath, V; Moghaddas, F; De Nardo, D; Gray, PE; Masters, SL

Title:
A Mutation Outside the Dimerization Domain Causing Atypical STING-Associated Vasculopathy With Onset in Infancy

Date:
2018-07-06

Citation:
Saldanha, R. G., Balka, K. R., Davidson, S., Wainstein, B. K., Wong, M., Macintosh, R., Loo, C. K. C., Weber, M. A., Kamath, V., Moghaddas, F., De Nardo, D., Gray, P. E. & Masters, S. L. (2018). A Mutation Outside the Dimerization Domain Causing Atypical STING-Associated Vasculopathy With Onset in Infancy. FRONTIERS IN IMMUNOLOGY, 9 (JUL), https://doi.org/10.3389/fimmu.2018.01535.

Persistent Link:
http://hdl.handle.net/11343/270843

File Description:
Published version

License:
CC BY